| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g | |||
| Other Sizes |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Fusidic acid has not yet received marketing approval from the U.S. Food and Drug Administration (FDA), but topical and systemic formulations are available in other countries. Data on fusidic acid excretion in breast milk is outdated and not from rigorously designed studies, but the concentration of the drug in breast milk appears to be low after intravenous fusidic acid administration. When using topical products, ensure that the infant's skin does not come into direct contact with the treated area. Water-soluble creams or gels should only be applied to the breasts, as ointments may expose the infant to high concentrations of mineral oil through licking. Topical application of fusidic acid appears to be relatively ineffective for treating nipple pain and cracking. ◉ Effects on Breastfed Infants As of the revision date, no published information was found. ◉ Effects on Lactation and Breast Milk A small, randomized, non-blinded trial of mothers with nipple pain and cracking showed that applying fusidic acid ointment to the nipples after each breastfeeding session was far less effective than oral antibiotics (cloxacillin or erythromycin, for a 10-day course) (36% vs 79%). Furthermore, 43% of patients did not experience symptom improvement after using fusidic acid, compared to only 16% in the oral antibiotic group; 21% of patients experienced a worsening of their condition after using fusidic acid, compared to only 5% in the oral antibiotic group. |
|---|---|
| References |
|
| Additional Infomation |
Fusidate Sodium is the sodium salt of fusidic acid, an antibacterial antibiotic extracted from the fungus Fusidium coccineum, used as a topical medication for treating skin infections. It is an antibiotic isolated from the fermentation broth of Fusidium. (From Merck Index, 11th edition). Its mechanism of action is to inhibit translocation during protein synthesis. See also: Fusidic acid (with active moiety).
|
| Molecular Formula |
C31H47NAO6
|
|---|---|
| Molecular Weight |
538.69
|
| Exact Mass |
538.327
|
| Elemental Analysis |
C, 69.12; H, 8.79; Na, 4.27; O, 17.82
|
| CAS # |
751-94-0
|
| Related CAS # |
Fusidic acid;6990-06-3
|
| PubChem CID |
23672955
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
635.6ºC at 760 mmHg
|
| Flash Point |
197.6ºC
|
| LogP |
4.331
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
38
|
| Complexity |
1000
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
[Na+].O([H])[C@]1([H])C([H])([H])[C@@]2([H])/C(=C(/C(=O)[O-])\C([H])([H])C([H])([H])/C(/[H])=C(\C([H])([H])[H])/C([H])([H])[H])/[C@]([H])(C([H])([H])[C@]2(C([H])([H])[H])[C@@]2(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]3([H])[C@]([H])(C([H])([H])[H])[C@@]([H])(C([H])([H])C([H])([H])[C@]3(C([H])([H])[H])[C@@]21[H])O[H])OC(C([H])([H])[H])=O
|
| InChi Key |
HJHVQCXHVMGZNC-JCJNLNMISA-M
|
| InChi Code |
InChI=1S/C31H48O6.Na/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32;/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36);/q;+1/p-1/b26-20-;/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-;/m0./s1
|
| Chemical Name |
sodium (Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-3,11-dihydroxy-4,8,10,14-tetramethylhexadecahydro-17H-cyclopenta[a]phenanthren-17-ylidene)-6-methylhept-5-enoate
|
| Synonyms |
Fusidate Sodium; CEM102; CEM 102; CEM-102
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~185.64 mM)
DMSO : ≥ 100 mg/mL (~185.64 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (185.64 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8564 mL | 9.2818 mL | 18.5636 mL | |
| 5 mM | 0.3713 mL | 1.8564 mL | 3.7127 mL | |
| 10 mM | 0.1856 mL | 0.9282 mL | 1.8564 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
